Articles & stories

Therapeutic Journeys in Diabetes – 1Q23 claim trends

The proportion of patients starting GLP or GIP-GLP treatment without prior diabetes treatment has risen substantially in recent quarters.

Our European Pharma Team leverages the CS Healthcare Database to examine the growth in demand and accelerate trends for prescription diabetes medications, Ozempic and Wegovy. Investors have been interested in whether they are being used off-label broadly as a weight loss treatment, or whether high-profile examples mentioned in the media are in reality a limited population.